Peripheral substance P signaling through NK1 receptors specifically mediates heat hypersensitivity — but not cold or mechanical pain — in rat models of orofacial inflammatory and neuropathic pain.
~50% pain reduction with NK1 blockadeA peripherally restricted NK1 antagonist reduced both phases of formalin-induced facial pain by approximately 50% and abolished nerve injury-induced heat hyperalgesia
What the researchers found
The study revealed a highly specific pattern for peripheral substance P signaling in orofacial pain:
- Substance P (1 µg/50 µL) injected into the upper lip induced heat hyperalgesia but not cold hyperalgesia, mechanical hyperalgesia, or spontaneous pain behavior
- The NK1 receptor antagonist SR140333B (3 mg/kg, which does not cross the blood-brain barrier) reduced substance P-induced heat hyperalgesia, carrageenan-induced heat hyperalgesia, and both phases of the formalin response by ~50%
- SR140333B abolished heat hyperalgesia caused by infraorbital nerve constriction (trigeminal neuropathic pain model) but did not affect cold or mechanical hyperalgesia
- SR140333B did not reduce carrageenan-induced cold hyperalgesia
Because the NK1 antagonist cannot cross the BBB and substance P was injected peripherally, these results specifically demonstrate peripheral (not central) substance P/NK1 signaling in facial heat pain.
Why it matters
Facial pain conditions — including trigeminal neuralgia, TMJ disorders, and dental pain — are among the most debilitating chronic pain conditions. Understanding that peripheral substance P specifically mediates heat pain (but not other pain types) in the face provides a more nuanced target for drug development. NK1 receptor antagonists that work peripherally could potentially treat facial pain without the side effects of drugs that enter the brain.
How the study worked
Wistar rats received peripheral injections of substance P at varying doses (0.1–100 µg/50 µL) into the upper lip and were assessed for spontaneous nociceptive behavior, heat hyperalgesia, cold hyperalgesia, and mechanical hyperalgesia. The NK1 receptor antagonist SR140333B (which does not cross the blood-brain barrier) was administered systemically at 3 mg/kg. Inflammatory pain was modeled with carrageenan injection and formalin testing in the orofacial region. Neuropathic pain was modeled by constriction of the infraorbital nerve (trigeminal neuropathy).
What this study cannot tell us
The study was conducted in male Wistar rats, and pain processing may differ from humans, especially in the orofacial region. Only one NK1 antagonist was tested. The higher doses of substance P (up to 100 µg) failed to induce spontaneous pain, which may reflect dose-response complexities or species differences. The formalin test measures a chemically induced pain response that may not fully represent clinical inflammatory pain.
How to read the evidence
This is a well-designed preclinical study using multiple pain models and a peripherally restricted antagonist to isolate the mechanism. The consistent finding across inflammatory and neuropathic models strengthens the evidence, but clinical translation requires human studies.
When this study was published
Published in 2013, this study contributed foundational knowledge about peripheral substance P signaling in facial pain. The specificity of heat-only effects continues to inform pain research and drug development.
The bigger picture
This study adds important specificity to the substance P pain literature. While substance P is broadly implicated in pain transmission, this work demonstrates modality-specific effects — it selectively drives heat but not cold or mechanical pain in the face. The use of a BBB-impermeable NK1 antagonist elegantly isolates peripheral from central effects. This has implications for understanding trigeminal neuralgia, dental pain, and migraine, where substance P signaling in the peripheral trigeminal system is clinically relevant.
Questions still open
- Could peripherally restricted NK1 receptor antagonists be effective for treating trigeminal neuralgia or other facial pain conditions in humans?
- Why does peripheral substance P specifically mediate heat but not cold or mechanical hyperalgesia in the face?
- Would combining NK1 antagonists with other analgesics provide superior facial pain relief by addressing multiple pain modalities?
Common questions
Why is it important that the study used a drug that can't enter the brain?
Why does substance P only cause heat pain and not other types?
Read the original research
Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models.
Neuropeptides, 47(3), 199-206
Citation
Teodoro, Fernanda C; Tronco Júnior, Marcos F; Zampronio, Aleksander R; Martini, Alessandra C; Rae, Giles A; Chichorro, Juliana G. (2013). Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models.. Neuropeptides, 47(3), 199-206. https://doi.org/10.1016/j.npep.2012.10.005